Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study
- 1 December 2001
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 34, 21-23
- https://doi.org/10.1016/s0169-5002(01)00389-0
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III studyLung Cancer, 2001
- The Role of Induction (Neoadjuvant) Chemotherapy in Stage IIIA NSCLCChest, 1996
- Benefits of Neoadjuvant Chemotherapy in NSCLCChest, 1996
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancerCancer, 1995
- Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.Journal of Clinical Oncology, 1994
- Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.Journal of Clinical Oncology, 1994
- A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1994
- A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung CancerNew England Journal of Medicine, 1994
- Induction therapy for NSCLC: a consensus reportLung Cancer, 1991